BLK vs ZYME · P/E 27, rev $24.22B vs rev $76.3M
BlackRock Inc (BLK) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
BLK currently screens at market cap $172.19B and trailing P/E 26.6. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the BLK and ZYME stock pages for the full models.
Not investment advice.